Glaukos Reports Positive Three-Year Phase 3 Extension Data for Epioxa

Glaukos Corporation (GKOS) announced positive long-term results from a three-year Phase 3 extension study evaluating Epioxa, its single-dose treatment for the eye condition keratoconus. The data showed a sustained 1.9D Kmax improvement at the three-year mark, with no serious adverse events reported in the treated eyes. Additionally, 92% of the patients completed their third-year follow-up visit. The study also revealed that 29% of treated eyes gained two or more lines of best corrected visual acuity, while 20% achieved an improvement of three or more lines.

These long-term findings confirm the durable efficacy and safety of Epioxa from a single treatment session. By demonstrating long-lasting vision improvement without the need for additional interventions, the treatment could offer a highly favorable economic profile for clinics and patients alike. The absence of serious side effects over three years significantly reduces the risks associated with long-term use, which is expected to support clinician adoption, patient demand, and insurance reimbursement. Following the announcement, Glaukos Corp shares rose 6.59% to 172.2 USD.

Moving forward, the focus turns to the ongoing commercialization efforts for Epioxa. Investors and healthcare providers should monitor potential catalysts such as larger real-world data releases, updated clinical guidelines, and new reimbursement approvals, which could further drive revenue growth for the company.